Amylin Pharmaceuticals Inc.

San Diego, CA, United States

Amylin Pharmaceuticals Inc.

San Diego, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Amylin Pharmaceuticals Inc. and Astrazeneca | Date: 2017-01-04

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimers disease, fatty liver disease, short bowel syndrome, Parkinsons disease, cardiovascular disease, and other and disorders of the central nervous system.


Patent
Amylin Pharmaceuticals Inc. and Alkermes | Date: 2015-01-07

This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.


Patent
Amylin Pharmaceuticals Inc., Eli Lilly and Company | Date: 2016-08-26

The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1 (7-37), GLP-1 (7-37) analogs (e.g., GLP-1 (7-36)-NH_(2)) and the like. The GLP-1 receptor agonist compound may be exenatide.


Patent
Amylin Pharmaceuticals Inc. and Astrazeneca | Date: 2016-03-30

The present invention provides novel Pancreatic Polypeptide Family (PPF) polypeptides and methods for their use.


Patent
Amylin Pharmaceuticals Inc. and Astrazeneca | Date: 2016-08-11

The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance.


Patent
Astrazeneca and Amylin Pharmaceuticals Inc. | Date: 2014-03-03

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.


Patent
Amylin Pharmaceuticals Inc. and Astrazeneca | Date: 2015-05-13

Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microspheres encapsulating the exenatide.


Patent
Eli Lilly, Company and Amylin Pharmaceuticals Inc. | Date: 2015-06-02

The disclosure provides, among other things, the use of GLP-1 receptor agonist compounds to treat obstructive sleep apnea. The GLP-1 receptor agonist compounds may be exendins, exendin analogs, GLP-1 (7-37), GLP-1 (7-37) analogs (e.g., GLP-1 (7-36)-NH_(2)) and the like. The GLP-1 receptor agonist compound may be exenatide.


Patent
Amylin Pharmaceuticals Inc. and Astrazeneca | Date: 2016-06-08

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimers disease, fatty liver disease, short bowel syndrome, Parkinsons disease, cardiovascular disease, and other and disorders of the central nervous system.


Patent
Amylin Pharmaceuticals Inc. and Astrazeneca | Date: 2015-10-30

The present disclosure is directed to stable pharmaceutical formulations and uses thereof.

Loading Amylin Pharmaceuticals Inc. collaborators
Loading Amylin Pharmaceuticals Inc. collaborators